Yellow Fever Vaccination with Cultured Virus (17D) without Immune Serum 1

Abstract

Summary A year's experience in the production and application of a cultured yellow fever vaccine virus (17D), during which time more than 59,000 persons were inoculated, shows that there is now available a practicable, safe method of large-scale immunization. Any reaction to the vaccine is mild, generally consisting of headache, low-grade fever, and grippe-like pains, on the sixth or seventh day. No instances of delayed reaction to the vaccination have been encountered. Studies in the laboratory demonstrate that antibodies appear in the blood after the seventh and before the twenty-first days and persist for at least one year. Results of postvaccination protection tests indicate that approximately 95 per cent of those vaccinated under field conditions acquire immunity.